The Medicines Company (NasdaqGS:MDCO) will look for acquisitions. The Medicines Company raised $172.5 million in Public Offering of Shares. We intend to use the net proceeds from this offering to fund our development of inclisiran and for general corporate purposes. General corporate purposes may include the acquisition of complementary products, technologies or businesses, repayment and refinancing of debt, pre-commercial activities, working capital and capital expenditures.